1 / 4

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions. Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than 350,000 Patients. Do I have aggressive disease?. Do I need radiation?. Do I need surgery?.

kamil
Télécharger la présentation

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than 350,000 Patients Do I have aggressivedisease? Do I need radiation? Do I need surgery? Do I need chemotherapy? INVASIVE BREAST CANCER DCIS BREAST CANCER STAGE II/III COLON CANCER PROSTATE CANCER

  2. Oncotype DX Changed Treatment Decisions in Over One-Third of Breast Cancer Patients Leading to Less Toxicity and Healthcare Costs 1 text Treatment Plan Prior to Oncotype DX Treatment Plan AfterOncotypeDX Women Diagnosed with Breast Cancer 2 text • Over a 37% Change in Treatment Decisions 3 text • Chemotherapy recommended for 62% of patients Bullet 1 Bullet 2 1 grey Do I need chemotherapy? INVASIVE BREAST CANCER 3 halo 2 4 Key Chemotherapy No Chemotherapy * Based on meta-analysis of seven studies with 912 patients

  3. Accurate Prediction of Prostate Cancer Risk is Needed at Time of Biopsy Do I need surgery? PROSTATE CANCER

  4. Oncotype DX Genomic Prostate Score Provides Significant Clinical Advantages and Actionable Information Prostate Clinical Validation Study (American Urological Association Meeting May 2013) "These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis.” — Peter Carroll, M.D., M.P.H.Chair, Department of Urology, University of California, San Francisco and Lead Investigator 4 Optimized technology to analyze tiny needle biopsies Identified genes that predict disease aggressiveness and address tumor heterogeneity Established multiple biological pathways are highly significant Studied relevant patient populations Developed to answer critical treatment questions prior to intervention

More Related